Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Iloprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 2/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 2/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 2/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 1/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 1/20 | 1.00 |
| ▸ | PPARD | Q03181 | 2/20 | 0.64 |
| ▸ | PPARA | Q07869 | 2/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 12/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iloprost SCHEMBL4357 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL9769188 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL9718500 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL21509111 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL21509108 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL21509107 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL21509137 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL21509174 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL20687610 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Iloprost SCHEMBL15955636 | 1.00 | PTGIR (1.00) | PTGIRPTGER3PTGER2PTGER1PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304519-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | CHIROGATE INTERNATIONAL INC. (TW) | 2025-10-02 | — | — | US | disclosed |
| US-12428361-B2 | Processes and intermediates for the preparation of carbaprostacyclin analogues | CHIROGATE INTERNATIONAL INC. (TW) | 2025-09-30 | — | — | US | disclosed |
| US-12409183-B2 | Method of using iloprost for treating frostbite | BTG INTERNATIONAL INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12409184-B2 | Iloprost compositions and formulations thereof | BTG INTERNATIONAL INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4273131-B1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | CHIROGATE INT INC (TW) | 2025-07-02 | — | — | EP | disclosed |
| US-20250144117-A1 | ILOPROST COMPOSITIONS AND FORMULATIONS THEREOF | BTG INTERNATIONAL INC. (US) | 2025-05-08 | — | — | US | disclosed |
| US-20250099484-A1 | METHOD OF USING ILOPROST FOR TREATING FROSTBITE | BTG INTERNATIONAL INC. | 2025-03-27 | — | — | US | disclosed |
| US-12221411-B2 | Processes and intermediates for the preparation of carbaprostacyclin analogues | CHIROGATE INTERNATIONAL INC. (TW) | 2025-02-11 | — | — | US | disclosed |
| US-20240299413-A1 | METHOD OF TREATING SYSTEMIC SCLEROSIS WITH SYMPTOMATIC RAYNAUD'S PHENOMENON BY INTRAVENOUS OR SUBCUTANEOUS ILOPROST ADMINISTRATION | BTG INTERNATIONAL INC. | 2024-09-12 | — | — | US | disclosed |
| US-20240299414-A1 | SUBCUTANEOUS OR INTRAMUSCULAR INJECTION FORMULATIONS OF ILOPROST | BTG INTERNATIONAL INC. | 2024-09-12 | — | — | US | disclosed |
| EP-3661602-B1 | PHOSPHOLIPID ANALOGUES | KARL FRANZENS UNIV GRAZ (AT) | 2021-05-26 | — | — | EP | disclosed |
| US-10954255-B2 | Phospholipid analogues | KARL-FRANZENS-UNIVERSITAET GRAZ (AT) | 2021-03-23 | — | — | US | disclosed |
| US-20210038510-A1 | FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS | PULMOKINE, INC. | 2021-02-11 | — | — | US | disclosed |
| CN-111662318-A | Iloprost key intermediate and preparation method thereof | 上海医药工业研究院 | 2020-09-15 | — | — | CN | disclosed |
| EP-3658187-A1 | PROSTACYCLIN RECEPTOR AGONISTS FOR REDUCTION OF BODY FAT | Allergan, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20200157127-A1 | Phospholipid Analogues | KARL-FRANZENS-UNIVERSITAET GRAZ (AT) | 2020-05-21 | — | — | US | disclosed |
| WO-2019023605-A1 | PROSTACYCLIN RECEPTOR AGONISTS FOR REDUCTION OF BODY FAT | ALLERGAN, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-5049582-A | Prostacyclin derivatives with cytoprotective effect on liver, pancreas and kidney | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-09-17 | — | — | US | disclosed |
| US-4631276-A | Prostaglandins and prostacyclins, process for their preparation and their use as medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-12-23 | — | — | US | disclosed |
| US-4468395-A | Prostaglandins and prostacyclins, processer for their preparation and their use as medicaments | SCHERING, AKTIENGESELLSCHAFT (DE) | 1984-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428361-B2 | Processes and intermediates for the preparation of carbaprostacyclin analogues | PTGIS, PTGIR, PTGES | PTGIR 2/4885PTGER3 16/4885PTGER2 13/4885 |
| US-20250099484-A1 | METHOD OF USING ILOPROST FOR TREATING FROSTBITE | PTGIS, PTGIR, TBXA2R | PTGIR 2/4885PTGER3 32/4885PTGER2 29/4885 |
| US-20250144117-A1 | ILOPROST COMPOSITIONS AND FORMULATIONS THEREOF | PTGIS, PTGIR, TBXA2R | PTGIR 2/4885PTGER3 12/4885PTGER2 8/4885 |
| US-20240299414-A1 | SUBCUTANEOUS OR INTRAMUSCULAR INJECTION FORMULATIONS OF ILOPROST | PTGIS, PTGIR, PTGER1 | PTGIR 2/4885PTGER3 9/4885PTGER2 6/4885 |
| US-10954255-B2 | Phospholipid analogues | ELOVL3, SGMS1, FFAR3 | PTGIR 202/4885PTGER3 25/4885PTGER2 78/4885 |
| US-20240299413-A1 | METHOD OF TREATING SYSTEMIC SCLEROSIS WITH SYMPTOMATIC RAYNAUD'S PHENOMENON BY INTRAVENOUS OR SUBCUTANEOUS ILOPROST ADMINISTRATION | TBXA2R, PTGIR, PTGIS | PTGIR 2/4885PTGER3 29/4885PTGER2 13/4885 |
| US-20200157127-A1 | Phospholipid Analogues | ELOVL3, SGMS1, FFAR3 | PTGIR 202/4885PTGER3 25/4885PTGER2 78/4885 |
| US-12221411-B2 | Processes and intermediates for the preparation of carbaprostacyclin analogues | PTGIS, PTGIR, PTGES | PTGIR 2/4885PTGER3 16/4885PTGER2 13/4885 |
| US-12409183-B2 | Method of using iloprost for treating frostbite | PTGIS, PTGIR, TBXA2R | PTGIR 2/4885PTGER3 32/4885PTGER2 29/4885 |
| US-20210038510-A1 | FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS | PTGIR, PTGIS, PTGFR | PTGIR 1/4885PTGER3 74/4885PTGER2 30/4885 |
| US-20250304519-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | PTGIS, PTGIR, PTGES | PTGIR 2/4885PTGER3 16/4885PTGER2 13/4885 |
| US-12409184-B2 | Iloprost compositions and formulations thereof | PTGIS, PTGIR, TBXA2R | PTGIR 2/4885PTGER3 12/4885PTGER2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.